Saturday, July 3, 2021

Bharat Biotech concludes phase 3 Covaxin trial, claims 77.8% efficacy against COVID 19

Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19. It also added that Covaxin gives 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant.

from IndiaTV India: Google News Feed https://ift.tt/3yjjB2J
via
at
Labels:

No comments:

Post a Comment

Please do not enter spam link in the comment box. Suggestions are invited for improvement.

Subscribe to: Post Comments (Atom)

Republic Day 2024: French band, marching contingent and Rafale jets participate in parade | WATCH

Republic Day 2024 : As India's 75th Republic Day Parade kicked off in the national capital, a 30-member band contingent and a marching c...